Calculus VCT has invested into Destiny Pharma, a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention.

The Company is developing novel antimicrobial drugs from its “in-house” XF platform and also from recently acquired Biotherapeutic products that harness beneficial components of the human microbiome. They have two exciting late stage clinical assets and a range of earlier research programmes.

The net proceeds of this latest round will allow the Company to continue progress towards Phase 3 trials in its two lead, clinical assets, NTCD-M3 and XF-73 Nasal, and finalise regulatory plans, whilst also strengthening the balance sheet as the Company progresses partnering discussions in relation to NTCD-M3.